Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury

Archives of Physical Medicine and Rehabilitation

Volumn 77, Issue 5, 1996, Pages 461-466

  Meythaler, Jay M ^a   DeVivo, Michael J ^b   Hadley, Mark ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; MUSCLE RELAXANT AGENT; PLACEBO; SODIUM CHLORIDE;

ADULT; ARTICLE; BOLUS INJECTION; BRAIN INJURY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; MALE; MUSCLE HYPERTONIA; MUSCLE TONE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPASTICITY;

EID: 0029938594     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-9993(96)90034-9     Document Type: Article

References (46)

1. Young RR, Delwaide PJ. Spasticity (part one of two parts). N Engl J Med 1981;304:28-33.
2. Katz RT. Mechanisms, measurement, and management of spastic hypertonia after head injury. Phys Med Clin North Am 1992;3:319-35.
3. Kroin JS, Penn RD, Beissinger RL, Arzbaecher RC. Reduced spinal reflexes following intrathecal baclofen in the rabbit. Exp Brain Res 1984;54:191-4.
4. Terrence DV, Fromm GH. Complications of baclofen withdrawal. Arch Neurol 1981;38:588-9.
5. Wilson PR, Yaksh TL. Baclofen is antinociceptive in the spinal intrathecal space of animals. Eur J Pharmacol 1978;51:323-30.
6. Yaksh TL, Ramana Reddy SV. Studies in the primate on the analgetic effects associated with intrathecal actions of opiate, L-adrenergic agonists and baclofen. Anesthesiology 1981;54:451-67.
7. Young RR. Treatment of spastic paresis. N Engl J Med 1989;320:1553-5.
8. Kums JJM, Delhaas EM. Intrathecal baclofen infusion in patients with spasticity and neurogenic bladder disease. Preliminary results. World J Urol 1991;9:99-104.
9. Katz RT. Management of spasticity. Am J Phys Med Rehabil 1988;67:108-16.
10. Young RR, Delwaide PJ. Spasticity (part two of two parts). N Engl J Med 1981;304:96-9.
11. Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol 1985;17:107-16.
12. MacDonell RAL, Talolla A, Swash M, Grundy D. Intrathecal baclofen and the H-reflex. J Neurol Neurosurg Psychiatry 1989;52:1110-12.
13. Muller H, Ziersky J, Dralle D, Borner V, Hoffmann O. The effect of intrathecal baclofen on electrical muscle activity in spasticity. J Neurol 1987;234:348-52.
14. Knuttson E, Martensson A. Plasma and cerebrospinal fluid levels of baclofen at optimal therapeutic responses in spastic paresis. J Neurol Sci 1974;23:473-84.
15. Knuttson E, Lindblom U, Martensson A. Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci 1974;23:473-84.
16. Hattab JR. Review of European clinical trials with baclofen. In: Feldman RG, Young RR, Kiella WP, editors. Spasticity. Disordered Motor Control. Chicago: Year Book Medical Publishers, 1979:71-85.
17. Roy CW, Wakefield IR. Baclofen pseudopsychosis: case report. Paraplegia 1986;24:318-21.
18. Sandy KR, Gillman MH. Baclofen-induced memory impairment. Clin Neuropharmacol 1985;8:294-5.
19. Meythaler JM, Steers WD, Haworth CS, Tuel SM, Ray J. Use of intrathecal baclofen in familial spastic paraparesis [abstract]. Arch Phys Med Rehabil 1990;71:767.
20. Latash ML, Penn RD, Corcos DM, Gottlieb GL. Effects of intrathecal baclofen on voluntary motor control in spastic paresis. J Neursurg 1990;72:388-92.
21. Lazorthes Y, Sallerin-Caute B, Verdie J, Bastide R, Carillo J. Chronic intrathecal baclofen administration for control of severe spasticity. J Neurosurg 1990;72:393-402.
22. Meythaler JM, Steers WD, Tuel SM, Cross LL, Haworth CS. Continuous intrathecal baclofen in spinal cord spasticity: a prospective study. Am J Phys Med Rehabil 1992;71:321-7.
23. Meythaler JM, Steers WD, Tuel SM, Sesco DV, Haworth CS. Use of intrathecal baclofen in familial spastic paraparesis. Arch Phys Med Rehabil 1992;73:794-7.
24. Meythaler JM, Steers WD, Haworth CS, Tuel SM, Sesco DV: Limitations and complications in the use of intrathecal baclofen [abstract]. Arch Phys Med Rehabil 1990;71:771.
25. Coffey RJ, Cahill D, Steers W, Park TS, Ordia J, Meythaler JM, et al (The Intrathecal Baclofen Multicenter Study Group). Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993;78:226-32.
26. Coffey RJ, Penn RD, Hirsch R. Intrathecal baclofen for intractable spasticity of spinal origin: Preliminary results of a multicenter study. Stereotact Funct Neurosurg 1990;54/55:217-8.
27. Penn RD, Kroin JS. Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg 1987;66:181-5.
28. Frost F, Nanninga J, Penn R, Savoy S, Wu Y. Intrathecal baclofen infusion. Effect on bladder management programs in patients with myelopathy. Am J Phys Med Rehabil. 1989;68:112-5.
29. Latash ML, Penn RD, Corcos DM, Gattlieb GL. Short-term effects of intrathecal baclofen in spasticity. Exp Neurol 1989;103:165-72.
30. Loubser PG, Narayan RK, Sandin KJ, Donovan WH, Russel KD. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia 1991;29:48-64.
31. Ochs G, Strupper A, Meyerson BA, Linderoth B, Gybels F, Gardner BP, et al. Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study. J Neurol Neurosurg Psychiatry 1989;52:933-9.
32. Pardke B, Penn RD, Savoy SM, Corcos D. Functional outcome after delivery of intrathecal baclofen. Arch Phys Med Rehabil 1989;70:30-2.
33. Penn RD, Kroin JS. Intrathecal baclofen alleviates spinal cord spasticity [letter]. Lancet 1984;1:1078.
34. Penn RD, Kroin JS. Continuous intrathecal baclofen for severe spasticity. Lancet 1985;2:125-7.
35. Steers WD, Meythaler JM, Haworth CS, Park TS. Effects of acute bolus and chronic continuous intrathecal baclofen on genitourinary dysfunction due to spinal cord pathology. J Urol 1992;188:1849-55.
36. Muller H, Zierski J, Dralle D, Krauss D, Mutschler E. Pharmacokinetics of intrathecal baclofen. In: Muller H, Zierski J, Penn RD, editors. Local-spinal therapy of spasticity. Berlin: Springer-Verlag, 1988:223-6.
37. Penn RD, Savoy SM, Corcos DM, Latash M, Gottlieb G, Parke B, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989;320:1517-22.
38. Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991;265:1418-22.
39. Muller H, Zierski J, Dralle D, Hoffman O, Michaelis G. Pharmacokinetics of intrathecal baclofen. In: Muller H, Zierski J, Penn RD, editors. Local-spinal therapy of spasticity. Berlin: Springer-Verlag, 1988:155-214.
40. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-2.
41. Lee KC, Carson L, Kinnin E, Patterson V. The Ashworth scale: a reliable and reproducible method of measuring spasticity. J Neurol Rehabil 1989;3:205-9.
42. Sokol RR, Rohlf FJ. Biometry. San Francisco: W. H. Freeman, 1969.
43. Kroin JS, Penn RD: Cerebrospinal fluid pharmacokinetics of lumbar intrathecal baclofen. In: Lakke JPWF, Delhaas EM, Rutgers AWF, editors. Parenteral drug therapy in spasticity and parkinson's disease. Canforth: Parthenon Publishing, 1991:73-83.
44. Merrit JL. Management of spasticity in spinal cord injury. Mayo Clin Proc 1981;56:614-22.
45. Goldstein LB. Pharmacologic modulation of recovery after stroke: clinical data. J Neurol Rehabil 1991;5:129-40.
46. Muller H, Qierske J, Dralle D, Borner U, Hoffman O. The effect of intrathecal baclofen on electrical muscle activity in spasticity. J Neurol 1987;234:348-52.